JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
This is a prospective, open-label, randomized phase II clinical study which recruits unresectable recurrent or metastatic triple-negative breast cancer resistant to immunotherapy.
Epistemonikos ID: ec9a5dcc2c4f028d820b0b694cf3ad4ade51a618
First added on: Jan 01, 2025